CompletedNot Applicable

Stellate Ganglion Blockade for Refractory Chronic Migraine

Turkey (Türkiye)42 participantsStarted 2024-03-06

Plain-language summary

Stellate Ganglion Block (SGB) is an interventional anesthetic technique used to treat pain conditions affecting the head, face, neck, and upper extremities by temporarily blocking sympathetic nerve output. Ultrasound guidance improves anatomical visualization and enhances procedural safety. Emerging evidence suggests that repeated ultrasound-guided SGB may reduce headache intensity and frequency in migraine patients and may improve migraine-related disability. However, limited data exist regarding its role in highly treatment-resistant chronic migraine, particularly in patients who have not responded adequately to preventive pharmacological therapies and peripheral nerve block interventions. The primary objective of this study is to evaluate the clinical efficacy of ultrasound-guided SGB in patients with treatment-resistant chronic migraine. Secondary objectives include assessing changes in migraine-related disability and monitoring potential adverse events.

Who can participate

Age range

18 Years – 65 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18- 65 years of age, diagnosed with chronic migraine in accordance with ICHD-3 criteria, * used migraine preventive medication drugs and * other interventional algologic treatments that have been applied at least three months ago with insufficient benefit are volunteer patients. Exclusion Criteria: * Migraine according to ICHD-3 criteria has a history of primary headache other than migraine, * migraine preventive interventional treatment within the last 3 months and/or botulinum toxin A, nonpharmacological treatment (acupuncture, ozone, cognitive behavioral therapy, etc.), * injection infection at the site, * pregnancy or suspected pregnancy, * known allergy to local anesthetic drugs with a history of malignancy or cranial/cervical surgery, * bleeding-coagulation disorder or oral anticoagulants, * comorbid diseases that may cause headache (uncontrolled hypertension, intracranial lesions), * with diseases that may prevent compliance with treatment (psychiatric disorder, dementia) and * patients who did not accept the planned interventional treatment were excluded from the study will be released.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in Monthly Headache Days (MHD)

Timeframe: Baseline to 6 months

Trial details

NCT IDNCT06891118

SponsorAnkara City Hospital Bilkent

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-30

View on ClinicalTrials.gov More Headache, Migraine trials